医疗器械企业纷纷发力“基层市场+海外市场”

Group 1 - The core market for domestic medical device companies has traditionally been first-tier cities, but there is a shift towards grassroots and overseas markets as of mid-2025 [1] - As of August 2023, 131 medical device companies are listed on A-shares, with nearly 100 companies mentioning sales activities in grassroots markets in their semi-annual reports, compared to only 4 companies in the same period in 2024 [1] - 90 companies reported overseas business income, with 67 experiencing year-on-year growth and 70 increasing the proportion of overseas income [1] Group 2 - The price drop due to centralized procurement has stimulated demand in grassroots markets, prompting companies to adjust their market strategies and seek new growth points [2] - For instance, Guichuang Tongqiao Medical Technology Co., Ltd. reported a revenue of 482 million yuan in the first half of 2024, a 31.7% increase year-on-year, largely due to increased sales from winning bids in centralized procurement [2] - The company also noted a 25.0% increase in sales revenue for neurovascular intervention products and a 46.2% increase for peripheral vascular intervention products in the first half of 2025 [2] Group 3 - The government has emphasized the need to expand and balance medical resources, pushing for quality medical resources to flow to county hospitals and grassroots healthcare [3] - The penetration rate of medical devices in second, third, and fourth-tier cities is expected to increase as residents' living standards and medical consumption rise [3] - The grassroots market is seen as a new profit growth point for medical device companies due to the large number of grassroots healthcare institutions and the currently low level of medical device configuration [3] Group 4 - Expanding into overseas markets is viewed as essential for the growth of medical device companies, with 33 out of 131 companies achieving double-digit revenue growth, driven significantly by overseas markets [4] - For example, Shanghai United Imaging Healthcare Co., Ltd. reported overseas revenue of 1.142 billion yuan in the first half of 2025, a 22.48% increase, with overseas orders continuing to grow rapidly [4] - Dongfulong Technology Group Co., Ltd. achieved overseas revenue of 805 million yuan, a 63.25% increase, surpassing domestic market growth for the first time [4] Group 5 - Guichuang Tongqiao's CEO expressed a desire to build capabilities overseas by integrating professional networks and enhancing the company's reputation through quality products [5] - The Chinese medical device industry possesses advantages in talent, clinical resources, cost, and supply chain, presenting opportunities to reshape the global market [5] - The industry may see more mergers and acquisitions as a means of expansion in the future [5]